ClinicalTrials.gg
CompletedNCT03890432Updated Aug 12, 2025

GLUCOSAFE 2 - A New Tool for Nutritional Management and Insulin-therapy in the Intensive Care Unit (ICU)

An interventional study of GLUCOSAFE 2 and Local protocol control group with routine care in Critical Illness, Energy Supply; Deficiency, Severe and Protein Deficiency, sponsored by HEIDEGGER CP. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Primary conditionProtein DeficiencyRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Protein Deficiency
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Protein Deficiency.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by HEIDEGGER CP · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The survival and the outcomes of critically ill patients are strongly influenced by insulin-therapy and nutritional support. The GLUCOSAFE 2 pilot study, aims to test the performance and the security of the new GLUCOSAFE 2 software, developed by the model-based medical decision support of Aalborg University (Denmark) and adapted to the clinical needs in the intensive care unit (ICU) of the Geneva University Hospital (HUG). This new device is based on a mathematical model of the glucose-insulin metabolism and attempts to give advices for better glycaemia control and nutritional therapy. The GLUCOSAFE 2 study hypothesizes that the use of the Glucosafe 2 software will allow better glycaemia ("Time-in-target") control and better achievement of nutritional energy and protein targets in comparison to the local protocols.

02

Conditions studied

  • Critical Illness
  • Energy Supply; Deficiency, Severe
  • Protein Deficiency
  • Hypoglycemia
  • Hyperglycemia

Browse trials for

Keywords

  • Nutrition management
  • Glycaemia control
  • ICU
  • Software
  • Critical illness
  • Insulin-therapy
  • Critically ill patients
  • Blood glucose control
03

In context

Protein Deficiency Reclassified

21 studies on the registry are indexed under Protein Deficiency; 4 are open to participants now.

This study's enrollment of 213 is above the median of 71 across 18 interventional studies indexed under Protein Deficiency.

Browse Protein Deficiency studies →

Lead sponsor

HEIDEGGER CP is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Protein Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients ≥ 18 years admitted to the ICU with

  • An expected length of stay ≥ 72h
  • At least 1 blood glucose (BG) measurement ≥10 mmol/l or 2 BG measurement ≥ 8.5 mmol/l
  • signed by the subject/ legal representative, except for patients in the historical control group

Exclusion criteria

Exclusion Criteria:

  • Lack of legal consent or consent withdrawn, except for patients in the historical control group
  • Pregnant or breast feeding
  • Diabetic ketoacidosis or hyperosmolar state
  • Oral feeding
  • Fulminant hepatic failure
  • Medically to receive rapidly acting insulin by intravenous (iv) infusion or iv injection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    GLUCOSAFE 2

    Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.

    Device: GLUCOSAFE 2

  • Active comparator
    Local protocol control group

    Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.

    Device: Local protocol control group with routine care

  • Other
    Historical control group

    Retrospective data with standard care before the beginning of the pilot study in order to minimize the "cross-over" effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time.

    Device: Historical control group with routine care

Interventions

  • DeviceGLUCOSAFE 2

    Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy

  • DeviceLocal protocol control group with routine care

    Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.

  • DeviceHistorical control group with routine care

    Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.

06

What researchers measure

Primary outcomes

  1. Time-in-target (range: 5.0 - 8.5 mmol/l)

    Time spent in the glycaemia range of 5.0 - 8.5 mmol/l per day, per patient and in the cohort

    Time frame: During ICU stay, up to 15 days post-randomization.

Secondary outcomes

  1. Overall number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events

    Overall number of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events (per patient and in the cohort)

    Time frame: During ICU stay, up to 15 days post-randomization.

  2. Overall percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events

    Overall percentage of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events (per patient and in the cohort)

    Time frame: During ICU stay, up to 15 days post-randomization.

  3. Number of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance

    Overall number of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm)

    Time frame: During ICU stay, up to 15 days post-randomization.

  4. Percentage of mild (<3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia events due to non-compliance

    Percentage of mild (\<3.3 mmol/l) and severe (\<2.2 mmol/l) hypoglycemia events due to non-compliance (only in intervention arm)

    Time frame: During ICU stay, up to 15 days post-randomization.

  5. Time to normalize blood glucose (5.0-8.5 mmol/l)

    Three values \< 8.5 mmol/l as indicator for normalization

    Time frame: During ICU stay, up to 15 days post-randomization.

  6. Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l)

    Percentage of time with BG \> 8.5 mmol/l before and after normalization per patient and in the cohort.

    Time frame: During ICU stay, up to 15 days post-randomization.

  7. Percentage of time in the ICU (per patient and in the cohort) with hyperglycaemia (BG > 8.5 mmol/l) due to non compliance

    Percentage of time with BG \> 8.5 mmol/l before and after normalization per patient and in the cohort due to non compliance (only in the intervention arm).

    Time frame: During ICU stay, up to 15 days post-randomization.

  8. Number of hyperglycemic episodes after normalization (> 8.5 mmol/l)

    Three values \< 8.5 mmol/h as indicator for normalization

    Time frame: From normalization time during ICU stay, up to 15 days post-randomization.

  9. Number of hyperglycemic episodes after normalization (> 8.5 mmol/l) due to non compliance

    Three values \< 8.5 mmol/h as indicator for normalization

    Time frame: From normalization time during ICU stay, up to 15 days post-randomization.

  10. Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice

    Number of episodes (per patient and in the cohort) where a BG measurements is not followed up within 30 minutes by a request for Glucosafe 2 advice

    Time frame: During ICU stay, up to 15 days post-randomization.

  11. Number of episodes (per patient and in the cohort) where pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse.

    Number of episodes (per patient and in the cohort) when pumps were not set within 30 min according to Glucosafe2 advice accepted by the nurse.

    Time frame: During ICU stay, up to 15 days post-randomization.

  12. Number of advices given by GS2 which were accepted, accepted with modification, or rejected.

    Number of advices given by GS2 which were accepted, accepted with modification, or rejected.

    Time frame: During ICU stay, up to 15 days post-randomization.

  13. Frequency of daily and cumulated BG measurements per patient and in the cohort

    Frequency of BG measurements (per patient and in the cohort)

    Time frame: During ICU stay, up to 15 days post-randomization.

  14. Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort)

    Frequency of daily and cumulated adjustments of insulin and nutrition pump settings (per patient and in the cohort)

    Time frame: During ICU stay, up to 15 days post-randomization.

  15. Glycaemic variability

    Mean and standard deviation (SD) of blood glucose measurements. Daily maximum blood glucose difference.

    Time frame: During ICU stay, up to 15 days post-randomization.

  16. Protein goal achievements (80-100% of accumulated target) with a target of 1.3 g/kg of body weight per day.

    Percentage of proteins received per day and at the end of the ICU stay with a target of 1.3 g/kg of body weight per day.

    Time frame: During ICU stay, up to 15 days post-randomization.

  17. Caloric goal achievements (80-100% of the accumulated target) by indirect calorimetry (IC) or predictive formula if IC not feasible.

    Percentage of nutritional and non-nutritional calories received per day and at the end of the ICU stay with a target defined by IC or predictive formula if IC not feasible.

    Time frame: During ICU stay, up to 15 days post-randomization.

  18. Energy debt: difference between the defined energy target (80-100%, defined by IC or predictive formula) and the energy received (nutritional and non-nutritional)

    Per day and at the end of the ICU stay.

    Time frame: During ICU stay, up to 15 days post-randomization.

  19. Protein debt: difference between the defined protein target (1.3 g/kg of body weight/day) and the proteins received

    Per day and at the end of the ICU stay.

    Time frame: During ICU stay, up to 15 days post-randomization.

  20. Prediction of BG

    Prediction error as a function of time elapsed since last BG measurement, per patient, per cohort.measurement (per patient and per cohort).

    Time frame: During ICU stay, up to 15 days post-randomization.

07

Study locations

2 sites
  • Hôpitaux Universitaire de Genève
    Geneva, Canton of Geneva 1205, Switzerland
  • Service of Intensive Care, Geneva University Hospital,
    Geneva, Canton of Geneva 1211, Switzerland
08

References and documents

Publications

  • de Watteville A, Pielmeier U, Di Marco M, Gayet-Ageron A, Siegenthaler N, Parel N, Wozniak H, Primmaz S, Pugin J, Andreassen S, Heidegger CP. Glucosafe 2-A new tool for nutritional management and insulin-therapy in the intensive care unit: Randomized controlled study (the Glucosafe 2 protocol). PLoS One. 2025 Mar 4;20(3):e0316624. doi: 10.1371/journal.pone.0316624. eCollection 2025. PubMed 40036206 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jan 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Mar 26, 2019
StartActual
Jan 10, 2023
Primary completionActual
Jan 26, 2025
CompletionActual
Jan 26, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03890432
Lead sponsor
HEIDEGGER CP
Collaborators
Aalborg University
Responsible party
HEIDEGGER CP (Privat-Docent, Senior Lecturer, University Hospital, Geneva) — Sponsor-investigator
First posted
Mar 26, 2019
Start date
Jan 10, 2023
Primary completion
Jan 26, 2025
Completion
Jan 26, 2025
Last update
Aug 12, 2025

Study contacts

Claudia P. Heidegger, MD
principal investigator · University Hospital, Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion